首页 > 最新文献

Scandinavian Journal of Surgery最新文献

英文 中文
Radiological comparison of atelectasis formation and pleural effusion after open versus thoracoscopic minimally invasive esophagectomy. 切开与胸腔镜微创食管切除术后肺不张形成及胸腔积液的影像学比较。
IF 1.8 3区 医学 Q1 SURGERY Pub Date : 2025-06-01 Epub Date: 2025-04-11 DOI: 10.1177/14574969251331671
Christine J Hannan, Arnar Thorisson, Erland Östberg, Magnus Sundbom, Jakob Hedberg

Background: Esophagectomy is associated with pulmonary complications. This study evaluated if thoracoscopic minimally invasive esophagectomy (MIE) mitigates these risks by comparing pulmonary findings on postoperative computed tomography (CT) between open esophagectomy and MIE.

Method: Postoperative (day 5) thoracic CT from 40 patients (20 open and 20 MIE) who had undergone esophagectomy with epidural analgesia and right-sided thoracic drainage were reviewed. On an axial view, the areas of atelectasis and pleural effusion were measured at 1 and 5 cm above the right diaphragmatic dome and at the level of the carina. In addition, the total distribution of atelectasis and pleural effusion was estimated on an ordinal scale (0-5), with ≥3 considered clinically important.

Results: The groups were well-matched in terms of age, sex, and smoking status. There were no differences in the areas of atelectasis or pleural effusion for open surgery compared with MIE. The groups did not differ in the proportion of patients with clinically important atelectasis (right: 30% vs. 25%, left: 65% vs. 65%) or pleural effusion (right: 15% vs. 15%, left: 65% vs. 45%). More pleural effusion and atelectasis at the 1-cm level was present on the left side at day 5 in both open and MIE patients.

Conclusion: Despite major differences in surgical trauma and ventilation strategies between open and MIE, CT evaluation at day 5 was surprisingly similar. Less right-sided pleural effusion demonstrates the effect of surgical drains. We believe that the defined levels of measurement used in this study, performed at clear anatomical landmarks, can be of value in future studies.

背景:食管切除术与肺部并发症相关。本研究通过比较胸腔镜微创食管切除术(MIE)和开放式食管切除术的术后计算机断层扫描(CT)结果,评估微创食管切除术(MIE)是否减轻了这些风险。方法:回顾40例经硬膜外镇痛右侧胸腔引流的食管切除术患者术后(第5天)的胸部CT资料。在轴向视图上,在右侧膈穹窿上方1和5厘米处和隆突水平处测量肺不张和胸腔积液区域。此外,对肺不张和胸腔积液的总分布进行排序(0-5),≥3被认为具有临床重要性。结果:两组在年龄、性别和吸烟状况方面匹配良好。与MIE相比,开放手术中肺不张或胸腔积液的面积没有差异。两组在临床上重要的肺不张(右:30% vs. 25%,左:65% vs. 65%)或胸腔积液(右:15% vs. 15%,左:65% vs. 45%)的患者比例上没有差异。在开放和MIE患者中,第5天左侧出现更多的胸腔积液和1厘米水平的肺不张。结论:尽管开放和MIE在手术创伤和通气策略上存在重大差异,但第5天的CT评估却惊人地相似。右侧胸腔积液减少表明手术引流的效果。我们相信,在本研究中使用的明确的测量水平,在明确的解剖标志上进行,可以在未来的研究中有价值。
{"title":"Radiological comparison of atelectasis formation and pleural effusion after open versus thoracoscopic minimally invasive esophagectomy.","authors":"Christine J Hannan, Arnar Thorisson, Erland Östberg, Magnus Sundbom, Jakob Hedberg","doi":"10.1177/14574969251331671","DOIUrl":"10.1177/14574969251331671","url":null,"abstract":"<p><strong>Background: </strong>Esophagectomy is associated with pulmonary complications. This study evaluated if thoracoscopic minimally invasive esophagectomy (MIE) mitigates these risks by comparing pulmonary findings on postoperative computed tomography (CT) between open esophagectomy and MIE.</p><p><strong>Method: </strong>Postoperative (day 5) thoracic CT from 40 patients (20 open and 20 MIE) who had undergone esophagectomy with epidural analgesia and right-sided thoracic drainage were reviewed. On an axial view, the areas of atelectasis and pleural effusion were measured at 1 and 5 cm above the right diaphragmatic dome and at the level of the carina. In addition, the total distribution of atelectasis and pleural effusion was estimated on an ordinal scale (0-5), with ≥3 considered clinically important.</p><p><strong>Results: </strong>The groups were well-matched in terms of age, sex, and smoking status. There were no differences in the areas of atelectasis or pleural effusion for open surgery compared with MIE. The groups did not differ in the proportion of patients with clinically important atelectasis (right: 30% vs. 25%, left: 65% vs. 65%) or pleural effusion (right: 15% vs. 15%, left: 65% vs. 45%). More pleural effusion and atelectasis at the 1-cm level was present on the left side at day 5 in both open and MIE patients.</p><p><strong>Conclusion: </strong>Despite major differences in surgical trauma and ventilation strategies between open and MIE, CT evaluation at day 5 was surprisingly similar. Less right-sided pleural effusion demonstrates the effect of surgical drains. We believe that the defined levels of measurement used in this study, performed at clear anatomical landmarks, can be of value in future studies.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"258-265"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subtle Lisfranc: When is minimal displacement equal to stability, and does it matter? 微妙的Lisfranc:什么时候最小位移等于稳定性,这有关系吗?
IF 1.8 3区 医学 Q1 SURGERY Pub Date : 2025-06-01 Epub Date: 2025-03-19 DOI: 10.1177/14574969251326386
Tim Schepers, Esmee W M Engelmann, Jens A Halm
{"title":"Subtle Lisfranc: When is minimal displacement equal to stability, and does it matter?","authors":"Tim Schepers, Esmee W M Engelmann, Jens A Halm","doi":"10.1177/14574969251326386","DOIUrl":"10.1177/14574969251326386","url":null,"abstract":"","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"162-163"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to letter to the editor on emergency surgery influences oncological outcome in small intestinal neuroendocrine tumors. 致编辑关于急诊手术影响小肠神经内分泌肿瘤预后的信的回复。
IF 1.8 3区 医学 Q1 SURGERY Pub Date : 2025-06-01 Epub Date: 2025-04-12 DOI: 10.1177/14574969251333906
Frederike Butz, Martina T Mogl, Eva Maria Dobrindt
{"title":"Response to letter to the editor on emergency surgery influences oncological outcome in small intestinal neuroendocrine tumors.","authors":"Frederike Butz, Martina T Mogl, Eva Maria Dobrindt","doi":"10.1177/14574969251333906","DOIUrl":"10.1177/14574969251333906","url":null,"abstract":"","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"297-298"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The expanding role of surgery in metastatic disease: A modern perspective. 手术在转移性疾病中的作用:现代视角
IF 1.8 3区 医学 Q1 SURGERY Pub Date : 2025-06-01 Epub Date: 2025-06-24 DOI: 10.1177/14574969251347342
Malin Sund, Sheraz Yaqub
{"title":"The expanding role of surgery in metastatic disease: A modern perspective.","authors":"Malin Sund, Sheraz Yaqub","doi":"10.1177/14574969251347342","DOIUrl":"10.1177/14574969251347342","url":null,"abstract":"","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"113-114"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic and bariatric surgery for adolescents with severe obesity: Benefits, risks, and specific considerations. 重度肥胖青少年的代谢和减肥手术:益处、风险和具体注意事项。
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2025-03-01 Epub Date: 2024-11-17 DOI: 10.1177/14574969241297517
Kajsa Järvholm, Annika Janson, Pia Henfridsson, Martin Neovius, Lovisa Sjögren, Torsten Olbers

International and national guidelines recommend metabolic and bariatric surgery (MBS) as a treatment option for adolescents with severe obesity, but few countries offer MBS to adolescents in routine clinical care. This narrative review summarizes existing adolescent MBS guidelines and the available underpinning evidence. Two randomized trials and additional prospective studies have demonstrated efficacy and safety in adolescent MBS, and the health benefits appear to be similar or superior to outcomes in adults. However, there are specific challenges regarding the intervention during adolescence related to decision-making capacity and a peak in risk-taking behavior. Adolescents with severe obesity have-as a group-a mental health vulnerability, and specific nutritional concerns need to be addressed in relation to MBS. This review also describes how study findings can be translated into clinical care. We use Sweden as an example, where the National Board of Health and Welfare recommends MBS for selected adolescents with severe obesity aged 15 years or older. We present practical advice for implementing and integrating MBS in adolescents in the framework of multidisciplinary pediatric and adolescent care for obesity.

国际和国内指南均建议将代谢与减肥手术(MBS)作为重度肥胖症青少年的一种治疗选择,但在常规临床护理中为青少年提供代谢与减肥手术的国家却寥寥无几。这篇叙述性综述总结了现有的青少年代谢减重手术指南和现有的基础证据。两项随机试验和其他前瞻性研究已经证明了青少年间充质干细胞疗法的有效性和安全性,其对健康的益处似乎与成人相似或更胜一筹。然而,青少年时期的干预措施面临着与决策能力和冒险行为高峰期有关的特殊挑战。患有严重肥胖症的青少年作为一个群体,在心理健康方面比较脆弱,因此需要解决与营养支持计划有关的特殊营养问题。本综述还介绍了如何将研究结果转化为临床护理。我们以瑞典为例,瑞典国家健康与福利委员会建议对选定的 15 岁或以上患有严重肥胖症的青少年实施营养与健康计划。我们提出了在儿科和青少年肥胖症多学科治疗框架内对青少年实施和整合运动负荷管理的实用建议。
{"title":"Metabolic and bariatric surgery for adolescents with severe obesity: Benefits, risks, and specific considerations.","authors":"Kajsa Järvholm, Annika Janson, Pia Henfridsson, Martin Neovius, Lovisa Sjögren, Torsten Olbers","doi":"10.1177/14574969241297517","DOIUrl":"10.1177/14574969241297517","url":null,"abstract":"<p><p>International and national guidelines recommend metabolic and bariatric surgery (MBS) as a treatment option for adolescents with severe obesity, but few countries offer MBS to adolescents in routine clinical care. This narrative review summarizes existing adolescent MBS guidelines and the available underpinning evidence. Two randomized trials and additional prospective studies have demonstrated efficacy and safety in adolescent MBS, and the health benefits appear to be similar or superior to outcomes in adults. However, there are specific challenges regarding the intervention during adolescence related to decision-making capacity and a peak in risk-taking behavior. Adolescents with severe obesity have-as a group-a mental health vulnerability, and specific nutritional concerns need to be addressed in relation to MBS. This review also describes how study findings can be translated into clinical care. We use Sweden as an example, where the National Board of Health and Welfare recommends MBS for selected adolescents with severe obesity aged 15 years or older. We present practical advice for implementing and integrating MBS in adolescents in the framework of multidisciplinary pediatric and adolescent care for obesity.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"95-106"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Finnish translation, validation, and reproducibility of BREAST-Q modules relevant to breast cancer treatment. 与乳腺癌治疗相关的 BREAST-Q 模块在芬兰的翻译、验证和再现。
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2025-03-01 Epub Date: 2024-09-22 DOI: 10.1177/14574969241277636
Pauliina Homsy, Jussi Repo, Charlotta Kuhlefelt, Andrew Lindford, Hanna Ihalainen, Susanna Kauhanen, Tiina Jahkola

Background and objective: Breast cancer and its treatments can have a marked impact on the patient health-related quality of life. The aim of this study was to produce and validate Finnish versions of the breast-conserving treatment, mastectomy and breast reconstruction modules of the BREAST-Q, a patient-reported outcome tool designed specifically for women undergoing treatment for breast cancer.

Methods: The relevant BREAST-Q modules were translated to Finnish according to established guidelines. Altogether 777 preoperative women were recruited at the Breast Surgery Unit and the Plastic Surgery Unit of Helsinki University Hospital between December 2019 and March 2021. This included 541 patients scheduled for breast-conserving surgery, 86 for mastectomy, and 150 for breast reconstruction. Postoperative patients were recruited through a postal survey, approaching 500 women operated for breast cancer in 2017, including 250 women who had undergone breast-conserving surgery and 250 women who had undergone mastectomy, as well as 339 women who had undergone breast reconstruction between August 2017 and July 2019. The patients were invited to fill the BREAST-Q modules relevant to their treatment and the general health-related quality-of-life instrument SF-36. A repeat administration of the BREAST-Q was done 2 weeks later.

Results: A total of 665 (41%) women participated in the study, 339 (44%) preoperatively and 326 (39%) postoperatively. The BREAST-Q subscales showed high internal consistency with most Cronbach's alphas > 0.8. The repeatability of the subscales was excellent with most intra-class correlation coefficients > 0.75. Low or negligible correlation was observed between BREAST-Q subscales and SF-36 domains.

Conclusions: The Finnish version of the BREAST-Q modules breast-conserving treatment, mastectomy, and breast reconstruction performs well in assessing the health-related quality of life of women undergoing surgery for breast cancer or breast reconstruction.

背景和目的:乳腺癌及其治疗会对患者与健康相关的生活质量产生明显影响。本研究的目的是制作并验证芬兰语版的 BREAST-Q 模块中的保乳治疗、乳房切除术和乳房重建模块:方法:根据既定指南将相关的 BREAST-Q 模块翻译成芬兰语。2019年12月至2021年3月期间,赫尔辛基大学医院乳腺外科和整形外科共招募了777名术前妇女。其中包括 541 名计划接受保乳手术的患者、86 名计划接受乳房切除术的患者和 150 名计划接受乳房重建术的患者。术后患者是通过邮寄调查的方式招募的,调查对象为500名在2017年接受乳腺癌手术的女性,其中包括250名接受保乳手术的女性和250名接受乳房切除术的女性,以及339名在2017年8月至2019年7月期间接受乳房重建手术的女性。患者应邀填写了与其治疗相关的BREAST-Q模块和一般健康相关生活质量工具SF-36。2周后再次进行BREAST-Q问卷调查:共有 665 名(41%)妇女参加了研究,其中 339 名(44%)在术前,326 名(39%)在术后。BREAST-Q 分量表显示出较高的内部一致性,大多数 Cronbach's alphas > 0.8。各分量表的重复性极佳,大多数类内相关系数大于 0.75。BREAST-Q 分量表与 SF-36 领域之间的相关性较低,甚至可以忽略不计:芬兰版BREAST-Q模块在评估接受乳腺癌手术或乳房重建的妇女的健康相关生活质量方面表现良好。
{"title":"Finnish translation, validation, and reproducibility of BREAST-Q modules relevant to breast cancer treatment.","authors":"Pauliina Homsy, Jussi Repo, Charlotta Kuhlefelt, Andrew Lindford, Hanna Ihalainen, Susanna Kauhanen, Tiina Jahkola","doi":"10.1177/14574969241277636","DOIUrl":"10.1177/14574969241277636","url":null,"abstract":"<p><strong>Background and objective: </strong>Breast cancer and its treatments can have a marked impact on the patient health-related quality of life. The aim of this study was to produce and validate Finnish versions of the breast-conserving treatment, mastectomy and breast reconstruction modules of the BREAST-Q, a patient-reported outcome tool designed specifically for women undergoing treatment for breast cancer.</p><p><strong>Methods: </strong>The relevant BREAST-Q modules were translated to Finnish according to established guidelines. Altogether 777 preoperative women were recruited at the Breast Surgery Unit and the Plastic Surgery Unit of Helsinki University Hospital between December 2019 and March 2021. This included 541 patients scheduled for breast-conserving surgery, 86 for mastectomy, and 150 for breast reconstruction. Postoperative patients were recruited through a postal survey, approaching 500 women operated for breast cancer in 2017, including 250 women who had undergone breast-conserving surgery and 250 women who had undergone mastectomy, as well as 339 women who had undergone breast reconstruction between August 2017 and July 2019. The patients were invited to fill the BREAST-Q modules relevant to their treatment and the general health-related quality-of-life instrument SF-36. A repeat administration of the BREAST-Q was done 2 weeks later.</p><p><strong>Results: </strong>A total of 665 (41%) women participated in the study, 339 (44%) preoperatively and 326 (39%) postoperatively. The BREAST-Q subscales showed high internal consistency with most Cronbach's alphas > 0.8. The repeatability of the subscales was excellent with most intra-class correlation coefficients > 0.75. Low or negligible correlation was observed between BREAST-Q subscales and SF-36 domains.</p><p><strong>Conclusions: </strong>The Finnish version of the BREAST-Q modules breast-conserving treatment, mastectomy, and breast reconstruction performs well in assessing the health-related quality of life of women undergoing surgery for breast cancer or breast reconstruction.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"65-72"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Different biliary tract cancers, same operation: Importance of cancer origin in patients with hilar-invading tumors. 不同的胆道癌症,相同的手术:胆道侵犯性肿瘤患者癌症来源的重要性。
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2025-03-01 Epub Date: 2024-10-08 DOI: 10.1177/14574969241282480
Hasan Ahmad Al-Saffar, Hannes Jansson, Olof Danielsson, Carlos F Moro, Christian Sturesson

Background and aims: For patients with biliary tract cancer involving the hepatic hilum, major hepatic resection with extrahepatic bile duct resection may be required. In addition to perihilar cholangiocarcinoma (PHCC), the same extent of surgery is used in advanced gallbladder cancer (GBC) and intrahepatic cholangiocarcinoma (IHCC) with hilar involvement. Few studies compare prognostic factors and long-term outcomes across tumor types. This study compared risk characteristics and outcomes after surgery in all subtypes of biliary tract cancer with hilar involvement.

Methods: Patients with biliary tract cancer with hilar involvement undergoing major liver resection and extrahepatic bile duct resection between 2011 and 2021 at a single center were retrospectively analyzed. The primary postoperative outcome was overall survival. Secondary outcomes were recurrence-free survival and postoperative complications. Survival analysis was performed with Cox regression analysis and Kaplan-Meier method.

Results: One-hundred and eight patients were included. Seventy-three (67%) had PHCC, 24 (22%) had GBC, and 11 (10%) had IHCC. Hilar-invading IHCC and GBC had more adverse histopathological factors like lymph node positivity (p = 0.021), higher number of positive nodes (p = 0.043), and larger tumor size (p < 0.001) compared with PHCC. Peritoneal invasion and lymph node positivity were significant independent predictors for survival (p = 0.011 and p = 0.004, respectively). Median overall survival was 29 months for PHCC, 22 months for GBC and 21 months for IHCC (p = 0.53). IHCC tended to recur earlier (p = 0.046) than GBC and PHCC (6, 15, and 18 months, respectively).

Conclusion: Patients with biliary tract cancer with hilar involvement undergoing major liver resection and resection of extrahepatic bile ducts had similar overall survival regardless of subtype, while IHCC recurred earlier. Peritoneal cancer invasion was common in all subtypes, including PHCC, and was an independent prognostic factor. This finding may support routine reporting of peritoneal invasion-status in resected biliary tract cancer.

背景和目的:对于累及肝门的胆道癌患者,可能需要进行肝大部切除和肝外胆管切除。除了肝门周围胆管癌(PHCC)外,晚期胆囊癌(GBC)和肝门受累的肝内胆管癌(IHCC)也采用相同程度的手术。很少有研究对不同肿瘤类型的预后因素和长期疗效进行比较。本研究比较了所有亚型胆道癌伴肝门部受累的风险特征和术后预后:方法:对2011年至2021年间在一个中心接受肝脏大部切除术和肝外胆管切除术的肝门部受累胆道癌患者进行回顾性分析。术后的主要结果是总生存期。次要结果是无复发生存率和术后并发症。采用Cox回归分析和Kaplan-Meier法进行生存分析:结果:共纳入 108 名患者。73例(67%)为PHCC,24例(22%)为GBC,11例(10%)为IHCC。淋巴结阳性(p = 0.021)、阳性结节数量较多(p = 0.043)、肿瘤体积较大(p 结论:淋巴结阳性和阳性结节数量较多(p = 0.043)对胆道癌患者的预后影响更大:接受肝脏大部切除术和肝外胆管切除术的肝门部受累胆道癌患者,无论亚型如何,总生存期相似,而IHCC复发较早。腹膜癌浸润在所有亚型中都很常见,包括PHCC,并且是一个独立的预后因素。这一发现可能支持对切除胆道癌的腹膜侵犯状况进行常规报告。
{"title":"Different biliary tract cancers, same operation: Importance of cancer origin in patients with hilar-invading tumors.","authors":"Hasan Ahmad Al-Saffar, Hannes Jansson, Olof Danielsson, Carlos F Moro, Christian Sturesson","doi":"10.1177/14574969241282480","DOIUrl":"10.1177/14574969241282480","url":null,"abstract":"<p><strong>Background and aims: </strong>For patients with biliary tract cancer involving the hepatic hilum, major hepatic resection with extrahepatic bile duct resection may be required. In addition to perihilar cholangiocarcinoma (PHCC), the same extent of surgery is used in advanced gallbladder cancer (GBC) and intrahepatic cholangiocarcinoma (IHCC) with hilar involvement. Few studies compare prognostic factors and long-term outcomes across tumor types. This study compared risk characteristics and outcomes after surgery in all subtypes of biliary tract cancer with hilar involvement.</p><p><strong>Methods: </strong>Patients with biliary tract cancer with hilar involvement undergoing major liver resection and extrahepatic bile duct resection between 2011 and 2021 at a single center were retrospectively analyzed. The primary postoperative outcome was overall survival. Secondary outcomes were recurrence-free survival and postoperative complications. Survival analysis was performed with Cox regression analysis and Kaplan-Meier method.</p><p><strong>Results: </strong>One-hundred and eight patients were included. Seventy-three (67%) had PHCC, 24 (22%) had GBC, and 11 (10%) had IHCC. Hilar-invading IHCC and GBC had more adverse histopathological factors like lymph node positivity (p = 0.021), higher number of positive nodes (p = 0.043), and larger tumor size (p < 0.001) compared with PHCC. Peritoneal invasion and lymph node positivity were significant independent predictors for survival (p = 0.011 and p = 0.004, respectively). Median overall survival was 29 months for PHCC, 22 months for GBC and 21 months for IHCC (p = 0.53). IHCC tended to recur earlier (p = 0.046) than GBC and PHCC (6, 15, and 18 months, respectively).</p><p><strong>Conclusion: </strong>Patients with biliary tract cancer with hilar involvement undergoing major liver resection and resection of extrahepatic bile ducts had similar overall survival regardless of subtype, while IHCC recurred earlier. Peritoneal cancer invasion was common in all subtypes, including PHCC, and was an independent prognostic factor. This finding may support routine reporting of peritoneal invasion-status in resected biliary tract cancer.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"35-43"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A randomized double-blind noninferiority clinical multicenter trial on oral moxifloxacin versus placebo in the outpatient treatment of uncomplicated acute appendicitis: APPAC IV study protocol. 口服莫西沙星与安慰剂在门诊治疗无并发症急性阑尾炎的随机双盲非劣效性临床多中心试验:APPAC IV研究方案。
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2025-03-01 Epub Date: 2024-12-05 DOI: 10.1177/14574969241293018
Heidi Lund, Jussi Haijanen, Saku Suominen, Saija Hurme, Suvi Sippola, Tuomo Rantanen, Tero Rautio, Anne Mattila, Tarja Pinta, Pia Nordström, Jyrki Kössi, Imre Ilves, Paulina Salminen

Background: Antibiotic therapy is currently considered a safe and effective treatment alternative for computed tomography (CT)-confirmed uncomplicated acute appendicitis with recent studies reporting good results on both oral antibiotics only and outpatient management. Furthermore, there are promising pilot results on uncomplicated acute appendicitis management with symptomatic treatment (placebo). This trial aims to assess whether both antibiotics and hospitalization can be safely omitted from the treatment of uncomplicated acute appendicitis.

Methods: The APPAC IV (APPendicitis Acuta IV) trial is a randomized, double-blind, multicenter noninferiority clinical trial comparing oral moxifloxacin with oral placebo in an outpatient setting with a discharge directly from the emergency room (ER). Adult patients (18-60 years) with CT-confirmed uncomplicated acute appendicitis (absence of appendicolith, abscess, perforation, tumor, appendiceal diameter ⩾15 mm on CT, or body temperature >38 °C) will be enrolled in nine Finnish hospitals. Primary outcome is treatment success at 30 days, that is, the resolution of acute appendicitis resulting in discharge from the hospital without appendectomy during the 30-day follow-up evaluated using a noninferiority design with a noninferiority margin of 6 percentage points. Noninferiority will be evaluated using one-sided 95% confidence interval of proportion difference between groups. Secondary endpoints include postintervention complications, recurrent appendicitis after the 30-day follow-up, duration of hospital stay, admission to hospital and reason for admission, readmissions to emergency department or hospitalization, VAS pain scores, quality of life, sick leave, and treatment costs. The follow-up after discharge from the ER includes a phone call at day 1, and at 3-4 days, 30 days, and 1, 3, 5, 10, and 20 years. Those eligible patients, who decline to undergo randomization, will be invited to participate in a concurrent observational cohort study with follow-up at 30 days, and 1 and 5 years.

Discussion: To our knowledge, APPAC IV trial is the first large randomized, double-blind, noninferiority multicenter clinical trial aiming to compare oral antibiotics and placebo for CT-diagnosed uncomplicated acute appendicitis in an outpatient setting. The study aims to bridge the major knowledge gap on whether antibiotics and hospitalization or both can be omitted in the treatment of uncomplicated acute appendicitis.

Trial registration: The study protocol has been approved by the Clinical Trials Information System (CTIS) of the European Medicines Agency (EMA), study number: 2023-506213-21-00 and the trial has been registered in ClinicalTrials.gov, NCT06210269.

背景:抗生素治疗目前被认为是计算机体层扫描(CT)确诊的无并发症急性阑尾炎的一种安全有效的治疗选择,最近的研究报告了仅口服抗生素和门诊治疗的良好结果。此外,对无并发症急性阑尾炎进行对症治疗(安慰剂)的试点结果也很有希望。本试验旨在评估非并发症急性阑尾炎的治疗中是否可以安全地省略抗生素和住院治疗。方法:APPAC IV(急性阑尾炎IV)试验是一项随机、双盲、多中心非劣效性临床试验,比较口服莫西沙星与口服安慰剂在门诊直接从急诊室出院的情况下的疗效。成年患者(18-60岁)经CT证实无并发症的急性阑尾炎(CT上没有阑尾结石、脓肿、穿孔、肿瘤、阑尾直径小于或等于15毫米,或体温小于或等于38°C)将被纳入芬兰的九家医院。主要结局是30天的治疗成功,即在30天随访期间,急性阑尾炎的消退导致出院,无需阑尾切除术,采用非劣效性设计评估,非劣效性差为6个百分点。非劣效性评价采用组间比例差异的单侧95%置信区间。次要终点包括干预后并发症、随访30天后阑尾炎复发、住院时间、入院及入院原因、再次进入急诊科或住院、VAS疼痛评分、生活质量、病假和治疗费用。出院后的随访包括第1天、3-4天、30天、1、3、5、10和20年的电话随访。那些拒绝接受随机化的符合条件的患者将被邀请参加一项并发观察队列研究,随访时间为30天、1年和5年。讨论:据我们所知,APPAC IV试验是第一个大型随机、双盲、非低效性的多中心临床试验,旨在比较口服抗生素和安慰剂治疗门诊ct诊断的无并发症急性阑尾炎。本研究旨在弥合关于非并发症急性阑尾炎治疗是否可以省略抗生素和住院治疗或两者都可以的主要知识差距。试验注册:该研究方案已获得欧洲药品管理局(EMA)临床试验信息系统(CTIS)的批准,研究编号:2023-506213-21-00,试验已在ClinicalTrials.gov注册,编号:NCT06210269。
{"title":"A randomized double-blind noninferiority clinical multicenter trial on oral moxifloxacin versus placebo in the outpatient treatment of uncomplicated acute appendicitis: APPAC IV study protocol.","authors":"Heidi Lund, Jussi Haijanen, Saku Suominen, Saija Hurme, Suvi Sippola, Tuomo Rantanen, Tero Rautio, Anne Mattila, Tarja Pinta, Pia Nordström, Jyrki Kössi, Imre Ilves, Paulina Salminen","doi":"10.1177/14574969241293018","DOIUrl":"10.1177/14574969241293018","url":null,"abstract":"<p><strong>Background: </strong>Antibiotic therapy is currently considered a safe and effective treatment alternative for computed tomography (CT)-confirmed uncomplicated acute appendicitis with recent studies reporting good results on both oral antibiotics only and outpatient management. Furthermore, there are promising pilot results on uncomplicated acute appendicitis management with symptomatic treatment (placebo). This trial aims to assess whether both antibiotics and hospitalization can be safely omitted from the treatment of uncomplicated acute appendicitis.</p><p><strong>Methods: </strong>The APPAC IV (APPendicitis Acuta IV) trial is a randomized, double-blind, multicenter noninferiority clinical trial comparing oral moxifloxacin with oral placebo in an outpatient setting with a discharge directly from the emergency room (ER). Adult patients (18-60 years) with CT-confirmed uncomplicated acute appendicitis (absence of appendicolith, abscess, perforation, tumor, appendiceal diameter ⩾15 mm on CT, or body temperature >38 °C) will be enrolled in nine Finnish hospitals. Primary outcome is treatment success at 30 days, that is, the resolution of acute appendicitis resulting in discharge from the hospital without appendectomy during the 30-day follow-up evaluated using a noninferiority design with a noninferiority margin of 6 percentage points. Noninferiority will be evaluated using one-sided 95% confidence interval of proportion difference between groups. Secondary endpoints include postintervention complications, recurrent appendicitis after the 30-day follow-up, duration of hospital stay, admission to hospital and reason for admission, readmissions to emergency department or hospitalization, VAS pain scores, quality of life, sick leave, and treatment costs. The follow-up after discharge from the ER includes a phone call at day 1, and at 3-4 days, 30 days, and 1, 3, 5, 10, and 20 years. Those eligible patients, who decline to undergo randomization, will be invited to participate in a concurrent observational cohort study with follow-up at 30 days, and 1 and 5 years.</p><p><strong>Discussion: </strong>To our knowledge, APPAC IV trial is the first large randomized, double-blind, noninferiority multicenter clinical trial aiming to compare oral antibiotics and placebo for CT-diagnosed uncomplicated acute appendicitis in an outpatient setting. The study aims to bridge the major knowledge gap on whether antibiotics and hospitalization or both can be omitted in the treatment of uncomplicated acute appendicitis.</p><p><strong>Trial registration: </strong>The study protocol has been approved by the Clinical Trials Information System (CTIS) of the European Medicines Agency (EMA), study number: 2023-506213-21-00 and the trial has been registered in ClinicalTrials.gov, NCT06210269.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"3-12"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142786564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early-onset rectal cancer: Experience of a single-center, high-volume unit. 早期直肠癌:单中心、高容量单位的经验。
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2025-03-01 Epub Date: 2024-10-13 DOI: 10.1177/14574969241282543
Taru M Lehtonen, Laura E Koskenvuo, Anna H Lepistö

Background and objective: The incidence of early-onset colorectal cancer among the young (<50 years) has been reported to have risen in last decades. This retrospective study aimed to investigate the characteristics of early-onset rectal cancers (EO-RCs) and potential changes in proportion of EO-RCs, and further to report the mortality and recurrence rates of EO-RCs.

Methods: In the years 2007-2021, 2557 rectal cancer (RC) patients were operated in Helsinki University Hospital and of them 147 were 18-49 years old. Cumulative overall survival (OS), disease-specific survival, and disease-free survival were calculated using the Kaplan-Meier analysis.

Results: The percentual amount of the EO-RCs varied between 2.5% and 11.3% annually and there was no perceivable trend. Majority were adenocarcinomas (98.7%), of which 8.8% were mucinous. Predisposing factors such as Lynch syndrome, polyposis, or ulcerative colitis were seen in 26 patients (17.7%) and in 10 of 22 patients (45.5%) under 35 years. The cumulative 5-year OS was 91.9% in stage I, 93.3% in stage II, 86.7% in stage III, and 50.0% in stage IV disease. Metastatic recurrence was found in 22 cases (18.4%) and local recurrence in 8 patients (5.4%) and 6 patients had both.

Conclusions: In our cohort of 147 EO-RC patients, OS was good and the clinical course did not seem to differ much from the course of RC in general population.

背景和目的:早发结直肠癌在年轻人中的发病率(方法:2007-2021年间,赫尔辛基大学医院共为2557名直肠癌患者实施了手术,其中147人年龄在18-49岁之间。采用 Kaplan-Meier 分析法计算了累积总生存期(OS)、疾病特异性生存期和无病生存期:结果:EO-RC 的年增长率介于 2.5% 和 11.3% 之间,没有明显的趋势。大多数为腺癌(98.7%),其中8.8%为粘液腺癌。26名患者(17.7%)有林奇综合征、息肉病或溃疡性结肠炎等易感因素,22名患者中有10名(45.5%)年龄在35岁以下。I 期患者的累积 5 年生存率为 91.9%,II 期为 93.3%,III 期为 86.7%,IV 期为 50.0%。22例患者(18.4%)发现转移性复发,8例患者(5.4%)发现局部复发,6例患者同时发现转移性复发和局部复发:在我们的 147 例 EO-RC 患者中,OS 良好,临床病程似乎与普通人群的 RC 病程差别不大。
{"title":"Early-onset rectal cancer: Experience of a single-center, high-volume unit.","authors":"Taru M Lehtonen, Laura E Koskenvuo, Anna H Lepistö","doi":"10.1177/14574969241282543","DOIUrl":"10.1177/14574969241282543","url":null,"abstract":"<p><strong>Background and objective: </strong>The incidence of early-onset colorectal cancer among the young (<50 years) has been reported to have risen in last decades. This retrospective study aimed to investigate the characteristics of early-onset rectal cancers (EO-RCs) and potential changes in proportion of EO-RCs, and further to report the mortality and recurrence rates of EO-RCs.</p><p><strong>Methods: </strong>In the years 2007-2021, 2557 rectal cancer (RC) patients were operated in Helsinki University Hospital and of them 147 were 18-49 years old. Cumulative overall survival (OS), disease-specific survival, and disease-free survival were calculated using the Kaplan-Meier analysis.</p><p><strong>Results: </strong>The percentual amount of the EO-RCs varied between 2.5% and 11.3% annually and there was no perceivable trend. Majority were adenocarcinomas (98.7%), of which 8.8% were mucinous. Predisposing factors such as Lynch syndrome, polyposis, or ulcerative colitis were seen in 26 patients (17.7%) and in 10 of 22 patients (45.5%) under 35 years. The cumulative 5-year OS was 91.9% in stage I, 93.3% in stage II, 86.7% in stage III, and 50.0% in stage IV disease. Metastatic recurrence was found in 22 cases (18.4%) and local recurrence in 8 patients (5.4%) and 6 patients had both.</p><p><strong>Conclusions: </strong>In our cohort of 147 EO-RC patients, OS was good and the clinical course did not seem to differ much from the course of RC in general population.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"22-34"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnetic Resonance Imaging - Derived Psoas Muscle Area and Survival in Patients Treated Invasively for Peripheral Arterial Disease. 磁共振成像--外周动脉疾病侵入性治疗患者的腰肌面积和存活率。
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2025-03-01 Epub Date: 2024-10-21 DOI: 10.1177/14574969241282485
Minea Söderlund, Henni Huhtamo, Sara Protto, Jussi A Hernesniemi, Damir Vakhitov, Niku Oksala, Niina Khan

Background and aims: Psoas muscle parameters estimated from computed tomography images, as surrogates for sarcopenia, have been found to be associated with post-interventional outcomes after a wide range of cardiovascular procedures. The pre-interventional assessment in patients undergoing invasive treatment for peripheral arterial disease is increasingly often carried out with magnetic resonance imaging (MRI), and we therefore sought to investigate the predictive potential of MRI-derived psoas muscle area in this cohort.

Methods: A total of 899 patients with available sufficient quality pre-interventional MRI conducted within 6 months prior to treatment undergoing open, endovascular, or hybrid revascularization procedures for claudication and/or limb-threatening ischemia at Tampere University hospital between 2010 and 2020 were retrospectively studied in this single-center cohort study. The follow-up lasted until 17 June 2021. Psoas muscle areas were measured from the magnetic resonance images at the L4 level, and the reliability of muscle parameter measurements was tested with intraclass correlation coefficient analysis. The average psoas muscle area values (mean of left and right psoas surface areas) were z-scored and analyzed separately for men and women.

Results: The median follow-up time was 5.9 years (interquartile range (IQR) = 2.7-7.8), and the overall mortality count was 259 (28.8%) (29.5% n = 168/569 for men and 27.6% n = 91/330 for women). The intraclass correlation coefficient analysis showed excellent interrater reliability for psoas muscle measurements. The muscle surface areas were larger in men (mean = 7.58 cm2) compared to women (mean = 5.27 cm2) (p < 0.001). Higher psoas muscle area was associated with better survival in women (p = 0.003, hazard ratio (HR) = 0.71, 95% confidence interval (CI) = 0.6-0.9 per 1 SD), whereas in men, an independent association of the muscle parameter with mortality was not found.

Conclusions: MRI-derived psoas muscle area may be a prognostic factor for clinical use.

背景和目的:从计算机断层扫描图像中估算出的腰肌参数作为 "肌肉疏松症 "的替代指标,已被发现与多种心血管手术的介入后结果相关。对接受外周动脉疾病侵入性治疗的患者进行介入前评估时,越来越多地使用核磁共振成像(MRI),因此我们试图研究核磁共振成像得出的腰肌面积在这一人群中的预测潜力:在这项单中心队列研究中,我们回顾性研究了 2010 年至 2020 年间坦佩雷大学医院因跛行和/或肢体缺血而接受开放、血管内或混合血管再通术治疗的 899 名患者,这些患者在治疗前 6 个月内接受了高质量的介入前 MRI 检查。随访持续到 2021 年 6 月 17 日。研究人员通过 L4 水平的磁共振图像测量腰肌面积,并通过类内相关系数分析检验了肌肉参数测量的可靠性。对腰肌面积平均值(左右腰肌表面积的平均值)进行了z评分,并分别对男性和女性进行了分析:中位随访时间为 5.9 年(四分位间距 (IQR) = 2.7-7.8),总死亡率为 259 例(28.8%)(男性为 29.5% n = 168/569,女性为 27.6% n = 91/330)。类内相关系数分析表明,腰肌测量结果的校正间可靠性极佳。与女性(平均 = 5.27 平方厘米)相比,男性的肌肉表面积更大(平均 = 7.58 平方厘米)(p 结论:男性的腰肌表面积更大,女性的腰肌表面积更大:MRI 导出的腰肌面积可能是临床使用的预后因素。
{"title":"Magnetic Resonance Imaging - Derived Psoas Muscle Area and Survival in Patients Treated Invasively for Peripheral Arterial Disease.","authors":"Minea Söderlund, Henni Huhtamo, Sara Protto, Jussi A Hernesniemi, Damir Vakhitov, Niku Oksala, Niina Khan","doi":"10.1177/14574969241282485","DOIUrl":"10.1177/14574969241282485","url":null,"abstract":"<p><strong>Background and aims: </strong>Psoas muscle parameters estimated from computed tomography images, as surrogates for sarcopenia, have been found to be associated with post-interventional outcomes after a wide range of cardiovascular procedures. The pre-interventional assessment in patients undergoing invasive treatment for peripheral arterial disease is increasingly often carried out with magnetic resonance imaging (MRI), and we therefore sought to investigate the predictive potential of MRI-derived psoas muscle area in this cohort.</p><p><strong>Methods: </strong>A total of 899 patients with available sufficient quality pre-interventional MRI conducted within 6 months prior to treatment undergoing open, endovascular, or hybrid revascularization procedures for claudication and/or limb-threatening ischemia at Tampere University hospital between 2010 and 2020 were retrospectively studied in this single-center cohort study. The follow-up lasted until 17 June 2021. Psoas muscle areas were measured from the magnetic resonance images at the L4 level, and the reliability of muscle parameter measurements was tested with intraclass correlation coefficient analysis. The average psoas muscle area values (mean of left and right psoas surface areas) were z-scored and analyzed separately for men and women.</p><p><strong>Results: </strong>The median follow-up time was 5.9 years (interquartile range (IQR) = 2.7-7.8), and the overall mortality count was 259 (28.8%) (29.5% n = 168/569 for men and 27.6% n = 91/330 for women). The intraclass correlation coefficient analysis showed excellent interrater reliability for psoas muscle measurements. The muscle surface areas were larger in men (mean = 7.58 cm<sup>2</sup>) compared to women (mean = 5.27 cm<sup>2</sup>) (p < 0.001). Higher psoas muscle area was associated with better survival in women (p = 0.003, hazard ratio (HR) = 0.71, 95% confidence interval (CI) = 0.6-0.9 per 1 SD), whereas in men, an independent association of the muscle parameter with mortality was not found.</p><p><strong>Conclusions: </strong>MRI-derived psoas muscle area may be a prognostic factor for clinical use.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"44-55"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Scandinavian Journal of Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1